Injecting our mice with a designated treatment scheme (a single dose of 50 μL/100 μM i.v. in tail vein per week) of the same leptin receptor antagonist peptide (PEG-LPrA2) that was used in our in vitro chemotaxis experiments at other appropriate concentrations, our in vivo results demonstrate a non significant tendency of this peptide to reduce tumor sizes in obese and overweight mice. Here, LEPR is linked to neoplasm.